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Abstract
Hypoxia is a hallmark of solid tumours and a key physiological
feature distinguishing cancer from normal tissue. However, a
major challenge remains in identifying tractable molecular targets
that hypoxic cancer cells depend on for survival. Here, we used
SILAC-based proteomics to identify the orphan G protein-coupled
receptor GPRC5A as a novel hypoxia-induced protein that functions
to protect cancer cells from apoptosis during oxygen deprivation.
Using genetic approaches in vitro and in vivo, we reveal HIFs as
direct activators of GPRC5A transcription. Furthermore, we find
that GPRC5A is upregulated in the colonic epithelium of patients
with mesenteric ischaemia, and in colorectal cancers high GPRC5A
correlates with hypoxia gene signatures and poor clinical
outcomes. Mechanistically, we show that GPRC5A enables hypoxic
cell survival by activating the Hippo pathway effector YAP and its
anti-apoptotic target gene BCL2L1. Importantly, we show that the
apoptosis induced by GPRC5A depletion in hypoxia can be rescued
by constitutively active YAP. Our study identifies a novel HIF-
GPRC5A-YAP axis as a critical mediator of the hypoxia-induced
adaptive response and a potential target for cancer therapy.
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Introduction
Hypoxia (reduced tissue O2 levels) features prominently in patho-
physiologies associated with a perturbed blood supply and is an
important feature of solid tumours (Harris, 2002). Due to its cancer-
specific nature and key regulatory role in tumour growth, hypoxia
has been proposed as one of the best validated cancer-selective
targets not yet exploited in oncology (Wilson & Hay, 2011). Intratu-
moral hypoxia occurs as the pace of tumour growth outstrips O2
availability and is exacerbated by the developing tumour vascula-
ture, which is often poorly formed with aberrant blood flow
(Ruoslahti, 2002; McIntyre & Harris, 2015). Tumour cells in these
hypoxic regions switch on an adaptive transcriptional response
mediated primarily by the hypoxia-inducible factors (HIFs) that help
them survive and continue to grow (Bottaro & Liotta, 2003; Pouysse-
gur et al, 2006). However, as transcriptional regulators are consid-
ered difficult therapeutic targets, an attractive prospect would be to
identify druggable mediators of hypoxic cancer cell survival (Wilson
& Hay, 2011). In this study, we identify a new hypoxia-activated
GPCR signalling axis that enables colorectal tumour cells to survive
the microenvironmental stress of hypoxia. We show that GPRC5A
(G Protein-coupled Receptor Class C, Group 5, Member A)—an
orphan GPCR of poorly understood regulation and function—is a
bona fide transcriptional target of HIFs both in vitro and in vivo.
Importantly, we show that upregulation of GPRC5A during hypoxia
protects colorectal tumour cells from apoptosis by activating the
Hippo pathway effector YAP. Our findings uncover a previously
unappreciated role for GPRC5A as a key regulator of the adaptive
response to hypoxia. This highlights a HIF-GPRC5A-YAP axis as a cancer
cell vulnerability and an opportunity to exploit tumour-associated
hypoxia for therapy.
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Results
Hypoxia induces GPRC5A protein expression
Regions of hypoxia are frequently found in colorectal cancers
(Yoshimura et al, 2004; Dekervel et al, 2014), but previous omics
studies of hypoxia-mediated cellular responses have largely focused
on breast cancer cells (Mole et al, 2009; Djidja et al, 2014; Semenza,
2017). To identify novel hypoxia-induced proteins in colorectal
cancer cells, we performed SILAC-based proteomics in SW620 cells
grown in normoxia (21% O2) or hypoxia (1% O2). As shown in
Fig 1A (and Appendix Table S1), these experiments confirmed
hypoxia-induced expression of well-established HIF-regulated
proteins (e.g. carbonic anhydrase 9; CA9, ~ 2.6-fold) as well as
proteins not previously reported to be hypoxia-regulated, including
GPRC5A (~ 1.6-fold). In line with our proteomics data, Western
blotting confirmed GPRC5A to be induced by hypoxia (Fig 1B),
apparent as a series of bands [likely due to dimerisation and
post-translational modifications (Zhou & Rigoutsos, 2014)] that we
verified the identity of using GPRC5A siRNA (Fig 1C, note the non-
specific ~ 60 kDa band henceforth marked with an asterisk). As
reported for other cell types (Tao et al, 2007), immunofluorescence
revealed that GPRC5A localised to the plasma membrane in SW620
cells (Fig 1D). We confirmed the generality of GPRC5A upregulation
by hypoxia using panel of malignant and pre-malignant human
colorectal cell lines (Fig 1E). Although detectable levels of GPRC5A
protein were present in normoxia, GPRC5A was robustly upregu-
lated by hypoxia in all colorectal tumour cell lines tested (Fig 1E).
These data identify GPRC5A as a novel hypoxia-induced protein.
GPRC5A is a direct transcriptional target of HIFs
To address whether hypoxia-induced GPRC5A protein expression
was dependent on HIFs we depleted major HIF-a isoforms (HIF-1a
and HIF-2a). Low basal HIF-1/2a expression was detectable in
normoxia, but was strongly induced by hypoxia (Fig 1F). As previ-
ously reported (Raval et al, 2005), CA9 expression was preferen-
tially reduced by depletion of HIF-1a (Fig 1F). However, both basal
and hypoxia-induced GPRC5A protein expression levels were dimin-
ished by individual HIF-1a or HIF-2a depletion (Figs 1F, and EV1A
and B) and abolished by depletion of HIF-1/2a together (Fig 1F).
This indicates that GPRC5A is a shared target of both HIF-1/2.
Depletion of HIF-1b also diminished hypoxia-induced GPRC5A
protein levels (Fig 1G), and induction of GPRC5A protein expression
by hypoxia mimetic DMOG was HIF-1/2-dependent (Fig 1H). Quan-
titative transcript analysis following HIF-1/2a depletion confirmed
that GPRC5A mRNA was also dependent on HIFs (Figs 1I and J, and
EV1C and D). To assess whether GPRC5A represents a direct tran-
scriptional target of HIFs, we performed ChIP-qPCR to ascertain HIF
binding at the GPRC5A promoter using primers spanning an optimal
(Wenger et al, 2005) hypoxia response element (HRE; 50-B(A/G)
CGTGVBBB-30 [B = all bases except A; V = all bases except T]). In
line with GPRC5A representing a HIF target, we found that HIF-1a
bound a region of the GPRC5A promoter (103/+47 relative to the
TSS; Fig 1K) containing an optimal HRE (50-CACGTGGCTT-30,
58/49), and binding of both HIF-1a and RNAPII to this region
increased in hypoxia (Fig 1K). As controls, neither HIF-1a nor
RNAPII were recruited to a downstream non-regulatory region of
the GPRC5A gene locus (+30,762/30,911) during hypoxia (Fig 1K).
As positive controls, we confirmed hypoxia increased the binding of
RNAPII and HIF-1a to the CA9 promoter (Fig 1K), as described
previously. Taken together, these data strongly suggest that GPRC5A
is a novel and direct HIF transcriptional target.
GPRC5A is hypoxia/HIF-induced in vivo
Having identified GPRC5A as hypoxia/HIF-induced in vitro, it was
important to investigate whether this is also true in an in vivo
context. Firstly, we examined GPRC5A (and CA9) expression in
human colorectal tissue samples from patients with mesenteric
ischaemia, which is characterised by regions of acute O2 deprivation
(Kaidi et al, 2007). We validated antibodies for IHC using formalin-
fixed paraffin-embedded hypoxic SW620 cells depleted of GPRC5A
or CA9 (Fig 2A and B). In patients with mesenteric ischaemia, strong
GPRC5A staining was present in the colonic epithelium, but not in
normal tissue (Figs 2C and EV2). Using serial sections, CA9 staining
mirrored GPRC5A expression, confirming hypoxia (Figs 2C and
EV2). These findings support our in vitro data and suggest GPRC5A
is induced by hypoxia in vivo. Secondly, to further establish the asso-
ciation of GPRC5A with HIFs and hypoxia in vivo, we took advantage
of a mouse model where genes can be inducibly deleted specifically
in intestinal epithelial cells (Sansom et al, 2004; Jackstadt & Sansom,
2016). It was previously noted that conditional Apc deletion in the
intestine leads to Hif1a activation and increased carbonic anhydrase
9 expression (Newton et al, 2010). Quantitative transcript analyses
of Apc-deleted (Villin-CreERT2 Apcfl/fl) and Apc/Hif1a-deleted
(Villin-CreERT2 Apcfl/fl;Hif1afl/fl) intestinal tissue revealed that
Gprc5a mRNA expression was reduced by ~ 70% following Hif1a
deletion (Fig 2D). As expected, Hif1a preferred targets Car9 and
Egln3 expression were reduced by Hif1a deletion (Fig 2D), but Dll4
(a Hif2a target) was not affected (Fig 2D). These data indicate
that Gprc5a is an in vivo physiological target of Hif1a in mouse
intestinal epithelial cells. Interestingly, using an in vivo zebrafish
model, we found that a related homologue (gprc5ba) was induced in
a model of constitutive HIF activation (Fig 2E; Santhakumar et al,
2012) (Tg[fli1:eGFP;vhl/]) and upon exposure of Tg[fli1:eGFP]
zebrafish to hypoxia (Fig 2E and F). Finally, bioinformatic analysis
on a transcriptomics dataset (GSE24551) from 320 primary colorectal
cancers revealed that GPRC5A mRNA levels strongly correlated with
HIF and hypoxia gene signatures (Fig 2G and H). Furthermore, we
found that high GPRC5A transcripts closely correlated with poor
survival outcomes in colorectal cancer patients (Fig 2I). However,
while these data show an in vivo association between GPRC5A,
hypoxia gene signatures and patient outcomes, it is important to note
that this may be a reflection of GPRC5A’s regulation by HIF activity/
hypoxia in aggressive tumours, rather than necessarily indicating a
functional role (Kaelin, 2017). Taken together, our in vitro and
in vivo findings show that hypoxia and HIFs regulate GPRC5A and
that high GPRC5A expression is an indicator of poor prognosis in
colorectal cancer patients.
GPRC5A promotes hypoxic cancer cell survival
The elevation of GPRC5A levels during hypoxia implicates it in adap-
tive signalling such as evasion of apoptosis. Exposure of colorectal
cancer cells to hypoxia resulted in only a minor increase in apoptosis,
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Figure 1. Hypoxia induces GPRC5A directly via HIFs.
A SILAC-based proteomics data identify known (red) and novel (green) hypoxia-induced proteins in SW620 cells. One-sample t-test was performed.
B Western blotting confirmed GPRC5A as a hypoxia-induced protein in SILAC lysates.
C Validation of GPRC5A Western blot data using siRNA. *Non-specific band of ~60 kDa not depleted by GPRC5A siRNA.
D Confocal microscopy showing plasma membrane GPRC5A expression in hypoxic SW620 cells (scale bars: 75 lm).
E Western blotting showing GPRC5A upregulation by hypoxia in a panel of colorectal tumour cell lines.
F Basal & hypoxia-induced GPRC5A protein expression was decreased by HIF-1/2a depletion.
G Depletion of HIF-1b decreased GPRC5A protein upregulation in hypoxia.
H Hypoxia mimetic DMOG induced HIF-1/2a, CA9 and GPRC5A protein expression. Dual HIF-1/2a depletion reduced GPRC5A induction by DMOG.
I qRT–PCR demonstrating that GPRC5A mRNA was upregulated by hypoxia (n = 3). GPRC5A was normalised to HPRT (error bars  SD).
J qRT–PCR demonstrating that HIF-1/2a depletion decreased GPRC5A induction during hypoxia (n = 3). GPRC5A was normalised to HPRT (error bars  SD).
K ChIP-PCR analyses identify HIF-1a binding to the GPRC5A promoter region containing a putative optimal HRE (error bars  SD, n = 3).
Data information: Asterisks (*) indicate non-specific band. Level adjustments were made to images in Adobe Photoshop post-acquisition for clarity (equal changes
applied to the entire image). Representative examples of n = 3 independent experiments are shown.
Source data are available online for this figure.
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as determined by Western blotting for cleaved caspase-3 and PARP
(Fig 3A). Strikingly, however, cells with depleted GPRC5A displayed
substantial increases in these apoptotic markers upon exposure to
hypoxia (Fig 3A). We confirmed these phenotypes with independent
siRNAs that each caused similar hypoxia-specific increases in
caspase-3/PARP cleavage (Fig 3B) and produced corresponding
reductions in hypoxic cell growth and survival (Fig 3C). To rule out
off-target effects, we generated SW620 cells stably carrying a doxy-
cycline-inducible siRNA-resistant (via synonymous mutations)
GPRC5A (SW620:GPRC5Asi1R; Figs 3D and EV3A–C). Expression of
GPRC5Asi1R was resistant to siRNA-mediated knockdown (Fig 3D)






Figure 2. GPRC5A is hypoxia/HIF-induced in vivo.
A, B Expression of CA9 and GPRC5A in formalin-fixed paraffin-embedded hypoxic SW620 cells by IHC. Reduced CA9 and GPRC5A expressions with siRNA confirm
antibody specificity (scale bars: 200 lm).
C IHC analysis of serial sections from human colorectal tissue from patients with mesenteric ischaemia (strangulated colon). GPRC5A is co-expressed with CA9 in the
colonic epithelial cells (scale bars: 50 lm).
D Quantitative RT–PCR analysis of mouse intestinal tissue. Gene expression was normalised to housekeeping gene Tbp. Raw data from three independent
experiments (n = 3 mice) are shown (error bars  SEM).
E Tg[fli1:eGFP; vhl/] and Tg[fli1:eGFP] zebrafish embryos (5 days post-fertilisation) demonstrate excessive angiogenesis and increased expression of HIF target
genes (scale bars: 100 lm).
F gprc5ba was induced in vhl mutant zebrafish embryos and fli1:eGFP zebrafish embryos exposed to 5% O2 (vs. normoxia) for 24 h (RT–PCR).
G, H Bioinformatic analysis of transcriptomics dataset GSE24551. Gene set analyses reveal GPRC5A mRNA strongly correlated with HIF/hypoxia gene signatures. GSEA
datasets used were Semenza_HIF1_Targets (M12299) Broad_Hallmark_Hypoxia (M5891). Analysis was performed using R2 (http://r2.amc.nl).
I Kaplan–Meier curve following analysis of transcriptomics dataset GSE24551. Event-free survival is significantly reduced in patients with tumours expressing high
levels of GPRC5A mRNA. Analysis was performed using R2 (http://r2.amc.nl).
Data information: Level adjustments were made to images in Adobe Photoshop post-acquisition for clarity (equal changes applied to the entire image). Representative
examples of n = 3 independent experiments are shown.
Source data are available online for this figure.
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Figure 3. GPRC5A promotes hypoxic cancer cell survival.
A GPRC5A depletion markedly increases caspase-3 activation/PARP cleavage during hypoxia.
B Three independent siRNA sequences targeting GPRC5A induce caspase-3 activation/PARP cleavage during hypoxia.
C GPRC5A depletion reduces hypoxic cell growth/survival. Crystal violet cell assays show reduced cell growth/survival in GPRC5A-depleted cells during hypoxia (n = 3).
D Expression of an siRNA-resistant GPRC5A cDNA rescues hypoxic GPRC5A-depleted cells from apoptosis. Upper: doxycycline-induced expression of GPRC5Asi1R
rescues increased caspase-3/PARP cleavage induced by GPRC5A depletion in hypoxia. Lower: generation of an siRNA1-resistant GPRC5A cDNA by synonymous
mutations.
E GPRC5A depletion in hypoxia induces apoptosis as determined by the violet ratiometric membrane asymmetry probe/dead cell apoptosis assay and flow cytometry
(n = 3 independent experiments).
F Caspase inhibitor QVD prevented caspase-3 activation/PARP cleavage by GPRC5A depletion in hypoxia.
Data information: Asterisks (*) indicate non-specific band. Level adjustments were made to images in Adobe Photoshop post-acquisition for clarity (equal changes
applied to the entire image). Representative examples of n = 3 independent experiments are shown; data are presented as mean  SEM. One-way ANOVA with Tukey’s
multiple comparisons test was carried out in (C and F).
Source data are available online for this figure.
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GPRC5A depletion in hypoxia (Fig 3D). To accurately quantify the
apoptosis resulting from GPRC5A depletion, we used the violet ratio-
metric membrane asymmetry probe and flow cytometry (which we
validated and optimised using the apoptosis-inducing drug ABT-737
and caspase inhibitor QVD; Fig EV3D). In normoxia, GPRC5A deple-
tion modestly increased apoptosis compared with non-targeting
siRNA control (7.82%  1.34 vs. 2.17%  0.23, ~ 3.6-fold increase),
but this increased markedly in hypoxia (23.37%  2.06 vs.
1.84%  0.21; ~ 12.7-fold increase; Fig 3E). The pro-apoptotic effect
of GPRC5A depletion in hypoxia was further validated using the
caspase inhibitor QVD, which rescued the apoptotic phenotypes in
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These data strongly indicate that GPRC5A protects tumour cells from
apoptosis during hypoxia.
YAP is required downstream of GPRC5A for cancer cell survival
in hypoxia
To gain a mechanistic insight into how GPRC5A might promote cell
survival during hypoxia, we performed additional bioinformatic
analysis on transcriptomics dataset GSE24551. KEGG pathway and
gene ontology analyses revealed that GPRC5A mRNA expression
strongly correlated with genes related to Hippo signalling, particu-
larly in later stage tumours (Appendix Table S2). Since YAP is a
major downstream regulator of the Hippo pathway and is required
for the formation and growth of colorectal tumours (Rosenbluh
et al, 2012; Zanconato et al, 2016), we examined its regulation by
hypoxia and found increased total YAP protein in a panel of colorec-
tal tumour cell lines (Fig EV4A). To determine whether there was a
functional connection between GPRC5A and YAP in hypoxia, we
examined the stability of YAP during hypoxia in the presence and
absence of GPRC5A siRNAs. In control cells, YAP Ser397 phospho-
rylation decreased during hypoxia, indicating that hypoxia stabilises
YAP (Fig 4A). Remarkably, however, we found that in GPRC5A-
depleted cells, YAP phosphorylated at Ser397 persisted during
hypoxia, suggesting that the stabilisation of YAP during hypoxia is
dependent on GPRC5A (Fig 4A). To confirm this, we examined YAP
nuclear localisation and transcriptional activity using the 8× GTIIC-
luciferase (TEAD) reporter. Nuclear YAP levels increased during
hypoxia, and this was abrogated by GPRC5A depletion (Fig 4B).
Furthermore, GPRC5A depletion reduced hypoxia-induced TEAD
activity (Fig 4C) and expression of established YAP target genes
AREG, CYR61, CTGF and BCL2L1 (Fig EV4B–E).
Having shown that GPRC5A depletion reduces YAP activity
during hypoxia, we asked how GPRC5A might regulate YAP phos-
phorylation. The small GTPase RhoA has previously been reported
to be a positive upstream regulator of YAP activity (Park et al,
2015) via its inhibition of LATS1/2 kinases downstream of Ga12/13-
coupled receptors (Yu et al, 2012). In line with decreased YAP
Ser397 phosphorylation during hypoxia, we found that both acti-
vated (phosphorylated) LATS1 levels and total expression of
LATS1/2 decreased during hypoxia (as reported previously for
LATS2; Ma et al, 2015). However, the inhibitory effects of hypoxia
on both LATS activity and expression were prevented in cells
depleted of GPRC5A (Fig 4D). This suggests that GPRC5A depletion
may stabilise LATS1/2 leading to increased YAP phosphorylation. In
line with this, expression of a constitutively active (G14V) form of
RhoA was sufficient to reverse the inhibitory phosphorylation of
YAP caused by GPRC5A depletion in hypoxia (Fig 4E), and we saw
no additional increase in YAP phosphorylation in hypoxic GPRC5A-
depleted cells upon expression of a dominant negative (T19N) form
of RhoA (Fig EV4F). Interestingly, we noticed that expression of
constitutively active RhoA enhanced GPRC5A expression in hypoxia
(Fig 4E), suggesting that activation of YAP may further increase
GPRC5A expression via a positive feedback loop. These data suggest
that RhoA is likely to act downstream of GPRC5A in hypoxia to
promote YAP stabilisation and activity.
To determine whether YAP activation downstream of GPRC5A
signalling has an anti-apoptotic role during hypoxia, it was first
important to test whether hypoxic cancer cells require YAP for
survival. To do this, we treated cells with verteporfin, a drug previ-
ously established to inactivate the YAP pathway by disrupting YAP/
TEAD protein–protein interactions (Liu-Chittenden et al, 2012). As a
proof of principle, hypoxic SW620 cells were profoundly more sensi-
tive to verteporfin relative to normoxia controls (Fig 4F). We then
asked whether YAP activation downstream of GPRC5A during
hypoxia was necessary for cell survival. Depletion of both GPRC5A
and YAP together revealed no additive effects on apoptosis pheno-
types relative to depletion of either protein alone (Fig 4G), suggest-
ing that YAP may be downstream of GPRC5A. To confirm this, we
tested whether YAP deficiency failed to protect cells from apoptosis
in a GPRC5A-dependent manner using GPRC5Asi1R-inducible cells.
As expected, doxycycline-induced expression of GPRC5Asi1R cDNA
rescued the cell growth and apoptosis phenotypes caused by
GPRC5A depletion in hypoxia (Fig 4H and I). Furthermore,
GPRC5Asi1R expression reversed the increased YAP Ser397 phospho-
rylation phenotype associated with GPRC5A depletion (Fig 4I).
Strikingly, although GPRC5Asi1R expression was able to rescue the
cell growth and apoptosis phenotypes of GPRC5A depletion in
hypoxia, these effects were reversed in the absence of YAP (Figs 4H
◀ Figure 4. GPRC5A promotes hypoxic cell survival via a novel HIF-GPRC5A-YAP axis.A Hypoxia-induced YAP stabilisation via Ser397 dephosphorylation was abrogated in GPRC5A-depleted cells.
B Hypoxia-induced nuclear localisation of YAP was attenuated in GPRC5A-depleted cells.
C Hypoxia stimulated TEAD activity (8× GTIIC-luc reporter), but this effect was reduced by GPRC5A depletion. A representative triplicate experiment is shown (n = 3).
D Hypoxia reduced LATS activity and expression, but this was prevented by GPRC5A depletion.
E Constitutively active RhoA (G14V) expression restored YAP stabilisation (Ser397 dephosphorylation) by hypoxia in GPRC5A-depleted cells.
F The YAP/TEAD inhibitor verteporfin selectively inhibited cancer cell survival in hypoxia by crystal violet assay (n = 3 independent experiments).
G YAP knockdown was sufficient to induce caspase-3 activation/PARP cleavage in hypoxia and was not further enhanced by GPRC5A depletion.
H Crystal violet assays show that YAP was required downstream of GPRC5A to promote cell survival. GPRC5A-depleted cells were rescued by expression of an siRNA-
resistant GPRC5A cDNA (GPRC5Asi1R), but this was prevented by co-depletion of YAP (n = 3 independent experiments).
I Expression of an siRNA-resistant GPRC5A rescued the critical phenotypes of GPRC5A depletion. GPRC5Asi1R expression prevented PARP cleavage in hypoxia as well as
restoring hypoxia-induced YAP stabilisation (Ser397 dephosphorylation); these phenotypes were reversed by YAP depletion.
J GPRC5A depletion attenuated hypoxia-induced BCL-XL expression.
K Constitutively active YAP (S127A) expression induced BCL-XL expression and prevented caspase-3 activation/PARP cleavage by GPRC5A depletion in hypoxia.
L GPRC5Asi1R expression restored BCL-XL expression and prevented the appearance of cleaved caspase-3 induced by GPRC5A depletion in hypoxia.
Data information: Asterisks (*) indicate non-specific band. Level adjustments were made to images in Adobe Photoshop post-acquisition for clarity (equal changes
applied to the entire image). Representative examples of n = 3 independent experiments are shown; data are presented as mean  SEM. One-way ANOVA with Tukey’s
multiple comparisons test was carried out in (F and H).
Source data are available online for this figure.
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and I, and EV4F). These data indicate that YAP acts downstream of
GPRC5A to promote cell survival during hypoxia.
We then asked how signalling downstream of the HIF-GPRC5A-
YAP axis might protect hypoxic cancer cells from apoptosis. Recent
reports have shown that BCL2L1 (encoding BCL-XL) is an important
anti-apoptotic downstream target gene of YAP (Imajo et al, 2012;
Rosenbluh et al, 2012). We observed a marked upregulation of
BCL2L1 transcripts and BCL-XL protein during hypoxia, which was
clearly absent in GPRC5A-depleted cells (Figs 4J and EV4C). To con-
firm that the apoptosis induced by GPRC5A depletion in hypoxia was
contingent on a failure to activate YAP, we performed rescue experi-
ments with a constitutively active YAP mutant (YAPCA, S127A).
Constitutively active YAP expression led to increased expression of
BCL-XL (and CYR61) and prevented the induction of apoptosis by
GPRC5A depletion in hypoxia (Fig 4K). Finally, we confirmed that
BCL-XL is downstream of the GPRC5A-YAP axis by expressing
GPRC5Asi1R, which restored BCL-XL expression and prevented apop-
tosis in hypoxic GPRC5A-depleted cells (Fig 4L). Overall, our findings
reveal a novel HIF-GPRC5A-RhoA-YAP axis that is important for
cancer cell survival during hypoxia (see synopsis model; Fig EV5).
Discussion
The development of solid tumours is accompanied by the onset of
hypoxia, making tumour cell evasion of apoptosis instigated by
hypoxic stress a central step during tumorigenesis (Harris, 2002;
Vaupel & Mayer, 2007; Hanahan & Weinberg, 2011; Semenza,
2012). For cells in developing tumours, hypoxia poses a selection
pressure that drives the acquisition of malignant traits, leading to
poor clinical outcomes and resistance to therapies (Harris, 2002;
Bottaro & Liotta, 2003; Vaupel & Mayer, 2007; Wilson & Hay, 2011).
Given hypoxia’s impact in shaping the progression of many
common solid tumours, understanding its influence on signalling
pathways involved in tumorigenesis is of major importance (Wilson
& Hay, 2011). While the HIF-driven transcriptional response is
known to be important for hypoxic adaptation, key unanswered
questions remain in understanding which genes downstream of
HIFs are most critical for cell survival, and how HIFs cooperate with
other important oncogenic pathways to orchestrate malignant beha-
viour. In addition, while hypoxia is widely thought to be a valid
cancer-specific therapeutic target (Wilson & Hay, 2011), one reason
it has not yet been fully exploited in the clinic is the lack of drug-
gable molecules downstream of the HIF transcriptional response.
Our work identifies GPRC5A as a previously unrecognised mediator
of tumour cell survival specifically during hypoxia. This represents
a new opportunity to exploit the notion of “conditional synthetic
lethality”, leveraging the cancer-associated nature of hypoxia to
selectively target tumour cells for death.
Although GPRC5A was originally identified as a retinoic acid-
inducible gene (Cheng & Lotan, 1998), the transcription factors
responsible for its regulation have remained unclear. Our work indi-
cates that HIFs are major regulators of GPRC5A expression. This
could explain its low levels in many normal tissues, as most tissues
are not hypoxic under normal physiological conditions (Wilson &
Hay, 2011). Furthermore, our data provide a molecular basis to
explain GPRC5A overexpression previously observed in solid
tumours, such as pancreatic cancers (Zhou & Rigoutsos, 2014; Zhou
et al, 2016). GPRC5A may also be induced by oncogenic pathways
upstream of HIFs such as RAS and PI3K pathways, or by other
conditions that result in “pseudo-hypoxia” (Sabharwal & Schu-
macker, 2014). Curiously, while Gprc5a constitutive knockout mice
(Gprc5a/) are reported to have a higher prevalence of sponta-
neous late-onset lung tumours than their wild-type littermates
(Tao et al, 2007; Kadara et al, 2010), a recent report showed that
the same Gprc5a/ mice are actually resistant to inflammation-
induced intestinal tumorigenesis, with dramatic reductions intesti-
nal tumours ≥ 3 mm (Zhang et al, 2017). Based on our mechanistic
findings, we speculate that without GPRC5A, such tumours would
be compromised in their ability to grow due to a failure to engage
the HIF-GPRC5A-YAP axis, thereby unable to survive hypoxic
stress. This is further supported by emerging evidence that
indicates pro-survival roles for YAP in oxygen-regulated processes
in a variety of contexts (Ma et al, 2015; Santinon et al, 2016; Wang
et al, 2017).
In our experiments, we found that activation of YAP by hypoxia
required GPRC5A, which establishes YAP as a major downstream
effector of HIF-driven GPRC5A-dependent cell survival. However,
this raises an interesting question: if activation of YAP enables cell
survival in hypoxia, why would HIFs—as the “primary sensors” of
oxygen deprivation—not activate YAP directly, rather than via a cell
surface GPCR? The answer to this may lie in GPRC5A’s potential
role as a “secondary metabolic sensor”, providing an additional
level of microenvironmental sensing downstream of HIFs that
connects the extracellular milieu to appropriate intracellular
responses. Indeed, Hippo–YAP signalling has recently been estab-
lished as a critical signalling branch downstream of certain GPCRs
in response to extracellular diffusible signals (Yu et al, 2012).
Furthermore, while GPRC5A remains an orphan receptor for which
no ligands have been identified, a study on the Drosophila GPRC5-
family orthologue BOSS suggests that this family of receptors may
be involved in sensing glucose to regulate sugar and lipid metabo-
lism (Kohyama-Koganeya et al, 2008). Since hypoxia is known to
trigger HIF-dependent expression of genes involved in maximising
glucose uptake during glycolysis, and glycolysis has been reported
to activate YAP (Enzo et al, 2015), GPRC5A may form part of the
HIF-driven metabolic shift during hypoxia by acting as a sensor for
extracellular cues to facilitate cellular adaptation and survival.
The discovery of the HIF-GPRC5A-YAP axis could have broad
implications for targeted oncology, because hypoxia occurs during
the development and progression of many common adult and child-
hood solid tumours. Furthermore, targeting GPRC5A may also
provide a new means to inhibit tumour-specific YAP activity. More-
over, since hypoxia frequently occurs in the therapy-resistant
regions of tumours where the utility of hypoxia-targeted drugs is
limited, the development of inhibitors to GPRC5A may lead to novel
cancer-selective drugs that could serve as adjuncts to conventional
chemo- and radiotherapy. Given that the HIF and Hippo–YAP path-
ways play important physiological roles in normal development as
well as during pathophysiological conditions, the crosstalk mediated
by GPRC5A reported here has functional consequences outside its
role in the context of tumorigenesis. For example, GPRC5A was
recently found to be highly expressed at the leading edge of wounds
(Aragona et al, 2017), so a more detailed understanding of its func-
tions may have implications for regenerative medicine, as well as
oncology.
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Materials and Methods
Cell culture experiments
The human colorectal tumour cell lines Caco2, DLD1, HT29,
HCT15, HCT116, LOVO, LS174T, RKO, SW480 and SW620 were
obtained from the American Type Culture Collection (ATCC; Rock-
ville, USA). The RG/C2 adenoma cell line was derived in this labora-
tory and was grown as described previously (Greenhough et al,
2010). Normoxia and hypoxia treatments were carried out in DMEM
(Gibco 12491-015) containing 10% FBS, supplemented with peni-
cillin (100 units/ml), streptomycin (100 lg/ml) and glutamine
(4 mM). Dimethyloxalylglycine (DMOG) was from Sigma; verte-
porfin was from MedChemExpress.
Hypoxia treatments
Hypoxia treatments were carried out at 37°C by flushing an InvivO2
300 hypoxia workstation/incubator (Ruskinn) with nitrogen to
create an atmosphere containing 94% N2, 5% CO2 and 1% O2. For
hypoxic treatment of zebrafish embryos (up to 5 days post-fertilisa-
tion), 5% O2 was used (Santhakumar et al, 2012).
SILAC labelling and proteomics
SILAC reagents were from Thermo Fisher Scientific; SILAC medium
and dialysed FBS were from Gibco. SW620 cells were grown in the
SILAC medium for at least six doublings to achieve full labelling.
Whole cell lysates were subjected to LC-MS/MS analysis on an LTQ
Orbitrap Velos mass spectrometer (Thermo) as described below.
LC-MS analysis
SILAC-labelled samples were pooled and ran on a 10% SDS–PAGE
gel, and the gel lane was cut into 10 equal slices. Each slice was
subjected to in-gel tryptic digestion using a DigestPro automated
digestion unit (Intavis), and the resulting peptides were fractionated
using an UltiMate 3000 nano-LC system in line with an LTQ Orbi-
trap Velos mass spectrometer (Thermo). Briefly, peptides in 1%
(vol/vol) formic acid were injected onto an Acclaim PepMap C18
nano-trap column (Thermo). After washing with 0.5% (vol/vol)
acetonitrile, 0.1% (vol/vol) formic acid peptides were resolved on a
250 mm × 75 lm Acclaim PepMap C18 reverse phase analytical
column (Thermo) over a 150 min organic gradient, using seven
gradient segments (1–6% solvent B over 1 min, 6–15% B over
58 min, 15–32% B over 58 min, 32–40% B over 5 min, 40–90% B
over 1 min, held at 90% B for 6 min and then reduced to 1% B over
1 min) with a flow rate of 300 nl/min. Solvent A was 0.1% formic
acid, and Solvent B was aqueous 80% acetonitrile in 0.1% formic
acid. Peptides were ionised by nano-electrospray ionisation at
2.1 kV using a stainless-steel emitter with an internal diameter of
30 lm (Thermo) and a capillary temperature of 250°C. Tandem
mass spectra were acquired using an LTQ Orbitrap Velos mass spec-
trometer controlled by Xcalibur 2.0 software (Thermo) and operated
in data-dependent acquisition mode. The Orbitrap was set to anal-
yse the survey scans at 60,000 resolution (at m/z 400) in the mass
range m/z 300–2,000 and the top ten multiply charged ions in each
duty cycle selected for MS/MS in the LTQ linear ion trap. Charge
state filtering, where unassigned precursor ions were not selected
for fragmentation, and dynamic exclusion (repeat count, 1; repeat
duration, 30 s; exclusion list size, 500) were used. Fragmentation
conditions in the LTQ were as follows: normalised collision energy,
40%; activation q, 0.25; activation time, 10 ms; and minimum ion
selection intensity, 500 counts.
Proteomics data analysis
Raw data files were processed and quantified using Proteome
Discoverer software v1.4 (Thermo) and searched against the
UniProt Human database (122,604 entries) using the SEQUEST algo-
rithm. Peptide precursor mass tolerance was set at 10 ppm, and
MS/MS tolerance was set at 0.8 Da. Search criteria included
carbamidomethylation of cysteine (+57.0214) as a fixed modifi-
cation and oxidation of methionine (+15.9949) and appropriate
SILAC labels (2H4-Lys,




15N4-Arg for triplex) as variable modifications. Searches were
performed with full tryptic digestion, and a maximum of one missed
cleavage was allowed. The reverse database search option was
enabled, and all peptide data were filtered to satisfy false discovery
rate (FDR) of 5%.
Western blotting
Western blot analysis was performed as described previously (Peth-
erick et al, 2013) using the following antibodies: GPRC5A (1:2,000,
CST, 12968), b-actin (1:10,000, Sigma, A5316), HIF-1a (1:1,000, BD,
610959), HIF-1b (1:1,000, BD, 611078), HIF-2a (1:1,000, CST,
7096), PLOD2 (1:1,000, R&D, MAB4445), CA9 (1:5,000, Novus,
NB100-417), cleaved PARP (1:20,000, Abcam, ab32064), active
caspase-3 (1:1,000, CST, 96645), p-YAP S397 (1:5,000, CST, 13619),
YAP (1:5,000, CST, 14074), BCL-XL (1:1,000, BD, 556361), BCL-2
(1:200, Santa Cruz, SC-509), V5-tag (1:2,000, CST, 13202), CYR61
(1:2,000, Santa Cruz, SC-374129), RhoA (1:2,000, CST, 2117), lamin
A/C (1:10,000, Sigma, 4C11) and a-tubulin (1:10,000, Sigma,
T6199). Cells were washed with ice-cold PBS and lysed on ice for
10 min with Cell Signaling Technology lysis buffer (9803) supple-
mented with protease inhibitors and sonicated briefly. Equal protein
concentrations were resolved using sodium dodecyl sulphate–poly-
acrylamide gel electrophoresis (SDS–PAGE) and transferred to an
Immobilon-P polyvinylidene difluoride membrane (Millipore). For
GPRC5A Western blots, samples were not boiled.
Bioinformatics
Analysis of dataset GSE24551 (Sveen et al, 2011) was carried out
using R2: Genomics Analysis and Visualization Platform (http://r2.a
mc.nl). KEGG pathway and gene ontology (GO) analyses were
carried out using GPRC5A as the source gene in tumour samples
(n = 320). Gene set enrichment analysis (GSEA) datasets used were
Semenza_HIF1_Targets (M12299) Broad_Hallmark_Hypoxia (M5891)
and are available from http://software.broadinstitute.org.
Immunohistochemistry
Tissue blocks (formalin-fixed, paraffin-embedded tissue) were
obtained from the archives of the Department of Histopathology at
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the Bristol Royal Infirmary, Bristol, England, UK, after approval
from the local research ethics committee (REC reference: E5470).
These were sectioned by the Histology Services Unit at University of
Bristol. For antibody validation, following siRNA knockdown of
CA9 and GPRC5A, cell lines were formalin-fixed and paraffin-
embedded as described previously (Greenhough et al, 2010). Anti-
bodies were used at a 1:800 dilution. This study involves only using
archival, anonymised tissues blocks, held prior to 1 September
2006. From the Human Tissue (HT) Act code of practice for
research, the consent requirements of the HT Act are not retrospec-
tive. This means that legally it is not necessary to seek consent
under the HT Act to store or use an “existing holding” for a sched-
uled purpose. An existing holding is a material from the living or
deceased that was already held at the time the HT Act came into
force on 1 September 2006.
Transfection, siRNA and 8× GTIIC-luc reporter assays
Transfections were performed using Lipofectamine 2000 or
RNAiMax (Invitrogen) in Opti-MEM (Gibco). Cells were transfected
twice with siRNA (20 nM) in a 48-h period to maximise knock-
down; siRNAs to human GPRC5A, HIF1A, HIF2A/EPAS1, HIF1B/
ARNT, or validated non-targeting negative control are detailed in
Appendix Table S3. Briefly, cells were transfected overnight; normal
growth medium was replaced the next day followed by a further
transfection overnight. Twenty-four hours later, cells were treated
as indicated in figure legends. 8× GTIIC-luc (YAP/TEAD) reporter
activity was determined using a dual-luciferase reporter system
(Promega) as described previously (Kimura et al, 2016). Constructs
and methods for adenoviral expression of active YAP (S127A),
active RhoA (G14V) and dominant negative RhoA (T19N) have been
described previously (Kimura et al, 2016).
Cloning and establishment of stable cell lines
Site-directed mutagenesis (Genewiz) was used to generate GPRC5A
cDNA resistant to GPRC5A siRNA sequence 1 (termed GPRC5Asi1R).
The GPRC5A open reading frame was amplified from GPRC5Asi1R
using primers containing AvrII and BsrgI restriction sites
(Appendix Table S4), cloned into pCW57-GFP-2A-MCS (a kind gift
from Adam Karpf, Addgene plasmid #71783) and verified by DNA
sequencing (Source Biosciences). SW620 cells were lentivirally
infected and puromycin-selected (15 lg/ml) for 7 days. To obtain
near 100% expressing cells, SW620:GPRC5Asi1R were treated with
doxycycline (2.5 lg/ml) for 48 h prior to flow sorting based on
medium/high TurboGFP expression (self-cleaving from the pCW57-
GFP-2A-MCS plasmid) using a BD Influx cell sorter (Becton-
Dickinson).
Immunofluorescence
Confocal analysis of immunofluorescence was carried out as
described previously (Petherick et al, 2013). Hypoxia-treated cells
grown on coverslips were fixed with 4% paraformaldehyde (with
0.1% Triton X-100) and stained with GPRC5A (1:200, CST, 12968)
and secondary antibodies (1:2,000) prior to DAPI nuclear staining
and mounting slides. Images were processed in Adobe Photoshop
(as described in corresponding legends).
Quantitative reverse transcription-polymerase chain
reaction (qRT–PCR)
Following treatment, RNA was extracted using TRI reagent (Sigma),
chloroform and isopropanol. After purification using the TURBO
DNase kit (Ambion), complementary DNA was produced using the
MMLV reverse transcriptase kit (Promega). qRT–PCR was
performed using a SYBR Green PCR kit (Qiagen) in a Stratagene
MX3005P qPCR cycler (La Jolla). A list of primers used in the study
is provided in Appendix Table S4.
Chromatin immunoprecipitation (ChIP)
ChIP was carried out as described previously (Petherick et al, 2013).
Briefly, 1% formaldehyde-fixed chromatin from nuclear lysates was
sheared to a 500 bp average by sonication (Diagenode Bioruptor),
pre-cleared and subject to immunoprecipitation overnight at 4°C
with antibodies to normal mouse IgG (8 lg/ml, Millipore, 12-371),
RNA polymerase II (8 lg/ml, Millipore) and HIF-1a (8 lg/ml, BD,
610959). Samples were incubated for a further 1 h at 4°C with
Protein G Magnabeads (Invitrogen) and processed using a
DynaMag-2 magnetic particle separator (Invitrogen).
Flow cytometry (violet ratiometric membrane asymmetry assay)
Following treatments, cells were washed with PBS and incubated
with F2N12S at 200 nM and SYTOX AADvanced dead cell stain
(A35137; Life Technologies) for 5 min at room temperature (as per
the manufacturer’s instructions). Live, dead and apoptotic cells
were detected using a BD LSR II flow cytometer (Becton-Dickinson)
and FACSDiva software. 30,000 events were measured, and the data
were analysed using FlowJo v10 analysis software (Tree Star, Inc.).
Crystal violet cell growth assays
Cells were seeded into 96-well plates (in sextuplicate per condition).
Following treatments, cells were fixed for 10 min in 4%
paraformaldehyde, stained with in 0.5% crystal violet solution
(Sigma) and solubilised in 1% SDS solution before reading absor-
bance values at 595 nm.
Mouse and zebrafish experiments
All experiments were conducted with approval from the local ethical
review committee at the University of Bristol and in accordance
with the UK Home Office regulations (Guidance on the Operation of
Animals, Scientific Procedures Act, 1986). Mice (Mus musculus)
were from a mixed C57Bl6/J background and aged 6–10 weeks
when induced. Both sexes were used. Mice contained the following
inducible genetic modifications (floxed alleles): Villin-CreERT2
Apcfl/fl (Shibata et al, 1997; el Marjou et al, 2004) and Villin-
CreERT2 Apcfl/fl; Hif1afl/fl (Ryan et al, 1998) and induced with
tamoxifen at 6–10 weeks of age. The following induction regimes
were used: Apcfl/fl mice 80 mg/kg tamoxifen (intraperitoneal) on
day 0 and day 1; samples were generated on day 4 post-induction.
Total RNA was isolated from small intestinal tissue to generate cDNA
as described previously (Huels et al, 2015). Zebrafish (Danio rerio),
home bred, up to 5 days post-fertilisation larvae (therefore gender
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N/A), were fed paramecia/rotifer chow and maintained in a 14:10-
light/dark cycle at 28.5 Celsius. The transgenic zebrafish line
Tg(fli1:eGFP) was crossed onto the vhlhu2117 mutant background
(Watson et al, 2013) as described previously (van Rooijen et al,
2009). The transgenic zebrafish line Tg(fli1:eGFP) was crossed onto
the vhlhu2117 mutant background (Watson et al, 2013) as described
previously (van Rooijen et al, 2009).
Statistical analyses
For animal studies, where appropriate, the Experimental Design
Assistant (provided by the National Research Centre for the Replace-
ment Refinement and Reduction of Animals in Research) was used
to calculate sample size https://www.nc3rs.org.uk/experimental-de
sign-assistant-eda. No animals were excluded from the analysis. No
steps were taken to randomise sample allocation, and no randomi-
sation was used. There were no scoring experiments and no blind-
ing was done. The Shapiro–Wilk normality tests were carried out
for normal distribution. Standard deviation and standard error of
the mean where appropriate are indicated. Analyses using t-tests
(one-sample and Student’s) and ANOVA were performed as indi-
cated in figure legends (P-values are indicated). Data are expressed
as the mean  SD or SEM (as indicated in figure legends).
Data availability
Mass spectrometry proteomics data are available in the following
database: ProteomeXchange Consortium via PRIDE PXD009971
(https://www.ebi.ac.uk/pride).
Expanded View for this article is available online.
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